ethyl 4-oxo-1,4-dihydroquinoline-8-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 4-oxo-1,4-dihydroquinoline-8-carboxylate
• 英文别名: ethyl 4-oxo-1H-quinoline-8-carboxylate
• 化学式: C₁₂H₁₁NO₃
• 分子量: 217.224
• InChiKey: YQTIRBZCGDOUCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  溴甲苯 、 ethyl 4-oxo-1,4-dihydroquinoline-8-carboxylate 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 28.0h， 以80.7%的产率得到ethyl 4-(benzyloxy)quinoline-8-carboxylate
  参考文献：
  名称：

  的光还原性脱除ö从Oxyarene苄组Ñ通过辅助-Heterocycles ø -吡啶吡啶酮互变异构

  摘要：

  已经开发出了简便的光还原方案，可以从氧化芳烃N-杂环上的苄基O-保护基团去除能够使2- / 4- O-吡啶-2- / 4-吡啶酮互变异构的位置。蓝光照射，[Ru]或[Ir]光催化剂和水-乙腈溶液中的抗坏血酸可选择性地使各种芳基N-杂环脱苄基。抗坏血酸在反应中具有两个功能。一方面，它使N-杂环质子化，从而显着降低其还原电位，另一方面，它作为牺牲性还原剂。以CPCM-B3LYP / 6-31 + G **水平计算的还原势和自由能垒可以预测所研究底物的反应性。

  DOI：

  10.1021/acs.joc.7b02775
• 作为产物：
  描述：

  ethyl 4-(benzyloxy)quinoline-8-carboxylate 在 tris(bipyridine)ruthenium(II) dichloride hexahydrate 、 维生素 C 作用下， 以 水 、 乙腈 为溶剂， 反应 2.0h， 以36.2%的产率得到ethyl 4-oxo-1,4-dihydroquinoline-8-carboxylate
  参考文献：
  名称：

  的光还原性脱除ö从Oxyarene苄组Ñ通过辅助-Heterocycles ø -吡啶吡啶酮互变异构

  摘要：

  已经开发出了简便的光还原方案，可以从氧化芳烃N-杂环上的苄基O-保护基团去除能够使2- / 4- O-吡啶-2- / 4-吡啶酮互变异构的位置。蓝光照射，[Ru]或[Ir]光催化剂和水-乙腈溶液中的抗坏血酸可选择性地使各种芳基N-杂环脱苄基。抗坏血酸在反应中具有两个功能。一方面，它使N-杂环质子化，从而显着降低其还原电位，另一方面，它作为牺牲性还原剂。以CPCM-B3LYP / 6-31 + G **水平计算的还原势和自由能垒可以预测所研究底物的反应性。

  DOI：

  10.1021/acs.joc.7b02775

文献信息

• BMP INHIBITORS AND METHODS OF USE THEREOF
  申请人：THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：US20160046633A1

  公开（公告）日：2016-02-18

  The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

  本发明提供了BMP信号通路的小分子抑制剂。这些化合物可用于调节细胞生长、分化、增殖和凋亡，因此可用于治疗与BMP信号通路相关的疾病或病症，包括炎症、心血管疾病、血液病、癌症和骨病，以及调节细胞分化和/或增殖。这些化合物还可用于降低ApoB-100或LDL的循环水平，治疗或预防获得性或先天性高胆固醇血症或高脂蛋白血症；与脂质吸收或代谢缺陷相关的疾病、疾病或综合症；或由高脂血症引起的疾病、疾病或综合症。
• BMP inhibitors and methods of use thereof
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：US10017516B2

  公开（公告）日：2018-07-10

  The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

  本发明提供了 BMP 信号转导的小分子抑制剂。这些化合物可用于调节细胞生长、分化、增殖和凋亡，因此可用于治疗与 BMP 信号转导相关的疾病或病症，包括炎症、心血管疾病、血液病、癌症和骨骼疾病，以及调节细胞分化和/或增殖。这些化合物还可用于降低载脂蛋白B-100或低密度脂蛋白的循环水平，治疗或预防获得性或先天性高胆固醇血症或高脂蛋白血症；与脂质吸收或代谢缺陷相关的疾病、失调或综合症；或由高脂血症引起的疾病、失调或综合症。
• BMP Inhibitors and Methods of Use Thereof
  申请人：ALIMARDANOV ASAF

  公开号：US20170334918A1

  公开（公告）日：2017-11-23

  The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
• US9682983B2
  申请人：——

  公开号：US9682983B2

  公开（公告）日：2017-06-20
• [EN] NEW AMINOALCOHOL DERIVATIVES<br/>[FR] NOUVEAUX DERIVES D'AMINOALCOOL
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2002000622A2

  公开（公告）日：2002-01-03

  The present invention relates to a compound of formula (I): wherein X1 is bond or -OCH2-; X2 is -(CH2)n-, in which n is 1 or 2; X3 is bond, -O- or -NH-; R1 is phenyl, indolyl or carbazolyl, each of which is optionally substituted with one or two substituent(s) selected from the group consisting of hydroxy, halogen, nitro, amino, formyl, (lower)alkylsulfonylamino, aryl(lower)alkoxy and hydroxy(lower)alkyl; R2 is hydrogen or aryl(lower)alkyl; R3 is hydrogen or hydroxy(lower)alkyl; R4 is aryl, 4-quinolyl, phthalazinyl, quinazolinyl, cinnolinyl or naphthyridinyl, each of which is optionally substituted with one or two substituent(s) defined in the specification, or a salt thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.